Proposed Trials of Potential Interest

Proposed/Planning

1. ISCHEMIA-Heart Failure Planning Study

  • The ISCHEMIA Coordinating Center at NYU is currently planning for a new study! Drs. Stuart Katz, Judith Hochman, and Sripal Bangalore are pleased to introduce the ISCHEMIA-Heart Failure planning study funded by NHLBI (R34 HL141621-01A1). This study will explore the feasibility of conducting a future randomized clinical trial to evaluate revascularization strategies in patients with ischemic cardiomyopathy and reduced left ventricular ejection fraction.
  • Who will be asked to participate? ISCHEMIA sites that have reported onsite PCI and CABG capabilities. Are opportunities available to contribute to the proposed trial? Pilot data are currently being collected through various methods, such as interviews and surveys, and from a variety of sources, including industry experts, ISCHEMIA sites, and patients. We may reach out to your site to participate in the collection of pilot data as these opportunities arise. How will we use the pilot data? All pilot data collected will be used to optimize study design for a future international multisite clinical trial to compare the effects of myocardial revascularization with coronary artery bypass graft surgery (CABG) or percutaneous coronary intervention (PCI) on clinical outcomes in patients with ischemic cardiomyopathy with reduced ejection fraction. Interested in learning more? Please contact us at ISCHEMIA-HF@nyulangone.org to learn more about this exciting pilot study.

2. Smilowitz R34

  • The recently awarded Post-Operative Biomarker-Guided Precision Medicine for Cardiovascular Risk Reduction Study planning grant (PI: N. Smilowitz) will focus on the management of high-risk patients with myocardial injury after noncardiac surgery (MINS). This pilot randomized clinical trial will assign participants with MINS to low-dose rivaroxaban and high intensity statin versus usual care, to test strategies to reduce long-term cardiovascular risk in high-risk patients identified based on post-operative biomarker surveillance.